CB1 Endocytic Dwell Time: Why Receptor Movement Has a Timing Component
How long an activated CB1 receptor remains clustered with beta-arrestin before internalization can help shape its signaling. This cellular timing measure is different from how long THC remains detectable or how long a person experiences an effect.
What the timing measure describes
Piscura and colleagues’ 2023 review discusses endocytic dwell time: the interval associated with receptors clustering with beta-arrestins in clathrin-coated pits during internalization. The measurement concerns events at the cell membrane.
The review summarizes ligand-specific differences. WIN55,212-2 was associated with shorter dwell times and little beta-arrestin signaling, whereas 2-AG was associated with longer dwell times and greater beta-arrestin activation. These compounds should retain their identities: one is a synthetic agonist and the other an endogenous cannabinoid.
Receptor activation does not specify one signal
Two substances can act at CB1 while organizing different interactions with signaling and trafficking proteins. An account that reports only “CB1 activation” can therefore omit a meaningful difference in the cellular response.
The dwell-time observations offer a mechanism for functional selectivity. They do not show that one ligand is universally safer or that a particular signaling preference necessarily produces less tolerance to every behavioral effect.
Keep the cellular clock separate from clinical clocks
Dwell time is not a blood elimination half-life, a detection window or a recommended waiting interval after cannabis. Those questions involve different measurements and require their own supporting evidence.
The review presents the relevance of these timing differences to cannabinoid tolerance as a research implication. Connecting the cellular event to repeated-dose behavior requires additional evidence. A precise molecular measurement can be valuable without becoming an individual impairment test.
Related reading: CB1 Biased Signaling Describes Pathway Preference, Not Proven Clinical Selectivity.
Research cited
Piscura MK and colleagues. Mechanisms of Cannabinoid Tolerance (2023). This analysis draws on the review’s discussion of the cited experiments.
